If you have been reading about Research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
=== Intravenous injection === Progesterone has a very short elimination half-life of about 3 to 90 minutes when given by intravenous injection. An aqueous solution of progesterone for use by intravenous injection was once marketed by Schering AG under the brand name Primolut Intravenous.
Leucine is a branched-chain amino acid (BCAA) since it possesses an aliphatic side chain that is not linear. Racemic leucine had been subjected to circularly polarized synchrotron radiation to better understand the origin of biomolecular asymmetry. An enantiomeric enhancement of 2.6% had been induced, indicating a possible photochemical origin of biomolecules' homochirality.
The second group are criteria insensitive for minimal difference between RF values (if two compounds are not separated, such CRF functions will not indicate it). They are equal to zero in equal-spread state increase when situation is getting worse. There are:
Drugs can also be transferred through the skin (transdermal). Inhalers are also of interest, as for example, asthma drugs consist of macromolecules. Currently, the inhalation systems are undesirable to patients, and it is hoped that there will be advances in this delivery system at some time.
Mestanolone, also known as 17α-methyl-4,5α-dihydrotestosterone (17α-methyl-DHT) or as 17α-methyl-5α-androstan-17β-ol-3-one, is a synthetic androstane steroid and a 17α-alkylated derivative of dihydrotestosterone (DHT). It differs from DHT only by the presence of the methyl group at the C17α position. Close synthetic relatives of mestanolone include oxandrolone (2-oxa-17α-methyl-DHT), oxymetholone (2-hydroxymethylene-17α-methyl-DHT), and stanozolol (a derivative of 17α-methyl-DHT (mestanolone) with a pyrazole ring fused to the A ring).
Sources: en.wikipedia.org
=== Relationship === Rose's parents forbade their daughter from continuing to date Fred, but she defied their wishes, prompting them to visit Gloucestershire's social services agency to explain that their 15-year-old daughter was having a sexual relationship with an older man, and that they had heard rumours that she had begun to engage in prostitution at Fred's caravan. In response, Rose was placed in a home for troubled teenagers in Cheltenham in August 1969, and only permitted to leave under controlled conditions. When allowed to return home to visit her parents at weekends, Rose almost invariably took the opportunity to visit Fred. On her 16th birthday, Rose left the home for troubled teenagers to return to her parents while Fred was serving a thirty-day sentence for theft and unpaid fines. Upon his release, Rose left her parents' home to move into a flat in Cheltenham with Fred. Shortly thereafter, Fred collected Charmaine and Anne Marie from social services. Rose's father made one final effort to prevent his daughter from seeing Fred, and Rose was examined by a police surgeon in February 1970, who confirmed she was pregnant. In response, Rose was again placed into care but was discharged on 6 March on the understanding she would terminate her pregnancy and return to her family. Instead, Rose opted to live with Fred, resulting in her father forbidding his daughter from ever again setting foot in his household. Three months later Fred and Rose vacated the Cheltenham flat and moved to the ground-floor flat of a two-storey house at 25 Midland Road in Gloucester.
Christian – 76.7% (19,567 people) Muslim – 1.4% (363 people) Jewish – 0.7% (182 people) Hindu – 0.7% (168 people) Buddhist – 0.4% (94 people) Sikh – 0.2% (39 people) Any other religion – 0.2% (58 people) No religion – 13.3% (3,390 people) Religion not stated – 6.1% (1,555 people).
=== Controversy === The game faced scrutiny in Germany after being linked to the Erfurt school massacre in 2002 after it was found on the computer of the perpetrator, Robert Steinhäuser. Politicians, including Günther Beckstein, and media outlets, particularly Bild, then regularly referred to the game as Killerspiel 'killer game'. Calls for banning violent video games intensified, with politicians like Beckstein advocating for penalties against players. Media outlets like Frontal 21 on ZDF often portrayed players negatively. In 2002, Germany's BPjM considered indexing Counter-Strike but ultimately rejected it, concluding that the game's objectives could be achieved without violence and that its communication aspects were beneficial. Chancellor Gerhard Schröder criticized the decision as irresponsible. A Brazilian federal judge, Carlos Alberto Simões de Tomaz, ordered a ban on the sale of Counter-Strike and EverQuest in October 2007 arguing that the games "bring imminent stimulus to the subversion of the social order, attempting against the democratic state and the law and against public security". The order began to be enforced on January 17, 2008, but regional federal court order lifting the prohibition on the sale of Counter-Strike was published on June 18, 2009.
===== Cellulose ===== The carbon-bonded HIC of cellulose, as inherited from leaf water, has the potential to preserve the original meteoric water signal. This was first demonstrated in the 1970s. In a systematic survey across North America, tree cellulose δD was found to have temperature sensitivity 5.8‰/°C, similar to precipitation δD sensitivity of 5.6‰/°C. This spatial correlation may be complicated by local effects of soil evaporation and leaf transpiration, and the spatial gradient may not be representative of temporal changes in tree ring cellulose at a single place. The mechanism that generates the δD signal in cellulose from meteoric water is not fully understood, but at least includes leaf water transpiration, synthesis of carbohydrates, synthesis of cellulose from photosynthetic sugars, and exchange of sugars with xylem water. Modeling studies show that observed tree ring cellulose δD can be produced when 36% of the hydrogen in sugars can exchange with xylem water, and effects such as humidity and rainfall seasonality may complicate the cellulose δD proxy. Despite these complications, tree ring δD have been used for paleoclimate reconstructions of the past few millennia. For example, a tree ring cellulose δD records from pine trees in the White Mountains, California shows a 50‰ depletion from 6800 year ago to present.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.